SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma advances with arm acquiring 14.58% stake in scPharmaceuticals

23 Dec 2016 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 617.00, up by 7.80 points or 1.28% from its previous closing of Rs. 609.20 on the BSE.

The scrip opened at Rs. 613.30 and has touched a high and low of Rs. 618.95 and Rs. 611.40 respectively. So far 1,29,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23-Feb-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 647.00 and Rs. 608.10 respectively. The current market cap of the company is Rs. 1,48,187.00 crore.

The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 33.34% and 11.68% respectively.

Sun Pharmaceutical Industries’ wholly owned subsidiary has acquired 13,000,000 Series B Preferred Stock of scPharmaceuticals Inc. (equivalent to 14.58% fully diluted equity stake on conversion) by way of allotment. scPharmaceuticals Inc., is a United States pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. The consideration for Series B Preferred Stock acquired is $13 million.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.


Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×